Industry news

Astellas and Immunomic Therapeutics enter into agreement over LAMP-vax technology

Read time: 1 mins

Last updated:14th Oct 2015

Published:14th Oct 2015

Source: Pharmawand

Immunomic Therapeutics, a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma have entered into an exclusive worldwide license agreement to the LAMP-vax products for the treatment or prevention of allergic diseases in humans. The LAMP-vax technology enhances the effectiveness of DNA vaccines, which potentially enables effective vaccinations for a wide spectrum of diseases.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Ono Pharma to acquire Deciphera Pharma

Deciphera Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO), under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO (the “Acquisition”), for a total equity value of $2.4 billion

1 mins

Industry news

Xoma Corporation announces completion of acquisition of shares of Kinnate Biopharma Inc.

XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health

1 min

Industry news

Regeneron Pharma and Mammoth Biosciences collaborate on CRISPR based gene editing therapies.

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types

1 min

See all news